Menu ABOUT US Seres’ visionary team has been at the forefront of microbiome therapeutics for over a decade. Pioneering microbiome therapeutics for serious diseases Seres Therapeutics is a late-clinical stage biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize treatment of a wide range of diseases by modulating the function of the human microbiome. We are an exceptional team of drug development and microbiome experts. Our leadership team, Board of Directors and Scientific Advisory Board have vast experience in the discovery, development, regulatory approval and successful commercialization of a wide range of therapeutic products. Our mission is to transform the lives of patients worldwide with revolutionary microbiome therapeutics. BOARD OF DIRECTORS SCIENTIFIC ADVISORY BOARD PARTNERS Our leadership team Eric Shaff PRESIDENT, CHIEF EXECUTIVE OFFICER Kristin Ainsworth SVP, CORPORATE COMMUNICATIONS David Arkowitz EVP, CHIEF FINANCIAL OFFICER AND HEAD OF BUSINESS DEVELOPMENT John Auniņš Ph.D. SENIOR ADVISOR, BIOPROCESS & MANUFACTURING Kelly M. Brady VP, CLINICAL OPERATIONS Marcus Chapman SVP, CORPORATE OPERATIONS Gloria G. Cosgrove VP, QUALITY SYSTEMS Thomas J. DesRosier, Esq. EVP, CHIEF LEGAL OFFICER AND SECRETARY David Ege, Ph.D. EVP, CHIEF TECHNOLOGY OFFICER Matthew Henn, Ph.D. EVP, CHIEF SCIENTIFIC OFFICER Barbara McGovern, M.D. VP, MEDICAL AFFAIRS Carlo Tanzi, Ph.D. INVESTOR RELATIONS Jim Weston SENIOR REGULATORY ADVISOR Lisa von Moltke, M.D. EVP, CHIEF MEDICAL OFFICER Jennifer R. Wortman VP, CLINICAL DISCOVERY AND RESEARCH TECHNOLOGIES Jeff York VP, HUMAN RESOURCES Terri Young, Ph.D., R.Ph. EVP, CHIEF COMMERCIAL AND STRATEGY OFFICER OUR LEADERSHIP TEAM SCIENTIFIC ADVISORY BOARD PARTNERS Board of Directors Eric Shaff President, Chief Executive Officer Eric Shaff is the President and Chief Executive Officer of Seres. Mr. Shaff was previously the Executive Vice President, Chief Operating and Financial Officer of Seres. He has over 20 years of experience working in leadership roles in biotechnology finance, corporate development and capital markets. Prior to joining Seres, he was Vice President, Corporate Finance, at Momenta Pharmaceuticals, where he helped manage Momenta’s accounting, finance, planning and procurement functions, as well as contributing to Momenta’s investor relations efforts. Prior to joining Momenta, Mr. Shaff was Vice President, Finance, of Genzyme’s Rare Genetic Disease Division, responsible for a global portfolio of products. Mr. Shaff held several positions at Genzyme in business unit finance, corporate finance and corporate development. Prior to Genzyme, Mr. Shaff worked in corporate finance at Pfizer and worked in investment banking for Broadview International (now Jefferies LLC). Mr. Shaff serves on the board of directors of Sigilon Therapeutics, Inc. Mr. Shaff earned his B.A. from the University of Pennsylvania in political science and economics and his MBA with a concentration in finance from the Johnson Graduate School of Management at Cornell University. > EXPAND BIO Stephen Berenson Chairman of the Board of Directors Stephen Berenson is a Managing Partner at Flagship Pioneering and member of the firm’s Resource Allocation and Management Committees. Prior to Flagship, Mr. Berenson spent over three decades in various roles as an investment banker at J.P. Morgan. During his last 12 years at J.P. Morgan, Mr. Berenson was Vice Chairman of Investment Banking. He was also co-founder of J.P. Morgan’s Global Strategic Advisory Council and co-founder of the firm’s Board Initiative. Mr. Berenson currently also serves on the board of directors of Moderna, Inc. and CiBO Technologies, Inc. Mr. Berenson earned his S.B. in mathematics from the Massachusetts Institute of Technology. > EXPAND BIO Dennis Ausiello, M.D. Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School; Chair of Medicine, Emeritus at Massachusetts General Hospital > EXPAND BIO Grégory Behar CEO, Nestlé Health Science Greg Behar is the Chief Executive Officer of Nestlé Health Science. Prior to this role, he was President and Chief Executive Officer of Boehringer Ingelheim Pharmaceuticals Inc. (USA). Mr. Behar has also previously served as Corporate Vice President Region North European Union, Canada and Australasia (NECAR) at Boehringer-Ingelheim GmbH. Mr. Behar serves on the board of directors of Axcella Health Inc. He received his B.S. in mechanical engineering from the University of California, Los Angeles, his M.S. in mechanical engineering and manufacturing from EPFL in Switzerland, and his MBA from INSEAD in France. > EXPAND BIO Kurt Graves Former Chairman, President and CEO, Intarcia Therapeutics, Inc. > EXPAND BIO Paul Biondi Executive Partner, Flagship Pioneering Paul Biondi serves as Executive Partner and President of Pioneering Medicines at Flagship Pioneering where he has been since November 2019. Mr. Biondi joined Flagship Pioneering following a seventeen-year tenure at Bristol-Myers Squibb (BMS) where he was most recently the Senior Vice President of Strategy and Business Development. Prior to serving in the role of Senior Vice President of Strategy, from 2002 to 2015, Mr. Biondi held a series of other leadership roles within BMS’ Research and Development organization overseeing strategy, portfolio and project management, as well as clinical and business operations. Mr. Biondi holds a bachelor’s degree from Dartmouth College and an MBA from the J.L. Kellogg School of Management at Northwestern University. > EXPAND BIO Richard Kender Former Senior Vice President of Business Development and Corporate Licensing, Merck > EXPAND BIO Willard Dere, M.D. FACP Associate Vice President for Research and Professor of Internal Medicine, University of Utah Health Sciences > EXPAND BIO Meryl Zausner Former Executive Vice President and Chief Financial and Administrative Officer, Novartis Pharmaceuticals > EXPAND BIO OUR LEADERSHIP TEAM BOARD OF DIRECTORS PARTNERS Scientific advisory board Elhanan Borenstein, Ph.D. Professor of Computer Science and of Medicine, Tel Aviv University Charles Cooney, Ph.D. Emeritus Professor, Massachusetts Institute of Technology Andrew Goodman, Ph.D. C.N.H. Long Professor of Microbial Pathogenesis and Director of the Microbial Sciences Institute, Yale University Stephen Hanauer, M.D. Clifford Joseph Barborka Professor, Professor of Medicine (Gastroenterology and Hepatology), Northwestern Medicine, Feinberg School of Medicine Curtis Huttenhower, Ph.D. Professor of Computational Biology and Bioinformatics, Department of Biostatistics, School of Public Health, Harvard University Robert Jenq, M.D. Medical Oncologist; Assistant Professor at MD Anderson Cancer Center Marcel van den Brink, M.D., Ph.D. Head, Division of Hematologic Malignancies; Alan N. Houghton Professor in Immunology; Member, Memorial Sloan-Kettering Cancer Center Mark Wilcox, M.D. Professor of Medical Microbiology, University of Leeds, and Consultant Clinical Microbiologist, Leeds Teaching Hospitals NHS Trust OUR LEADERSHIP TEAM BOARD OF DIRECTORS SCIENTIFIC ADVISORY BOARD Partners Seres’ partnership with Nestlé Health Science, announced Jan. 11, 2016, pertains to C. difficile and IBD programs for markets outside of North America. Seres is partnering with the University of Texas MD Anderson Cancer Center and the Parker Institute for Cancer Immunotherapy, as announced Nov. 14, 2017, to develop microbiome therapies to improve the outcomes of cancer patients. Seres is partnering with CARB-X, as announced Nov. 7, 2017, and Memorial Sloan Kettering Cancer Center, as announced May 12, 2016, to progress the development of microbiome therapeutics to prevent serious bacterial infections and graft versus host disease in patients undergoing transplantation. © 2021 Seres Therapeutics Privacy Policy Terms of use Follow us on Linkedin Follow us on Twitter Follow us on Facebook